Nevertheless, as reported in cancer cells54, we found that Tubastatin A does not induce hyperacetylation of HSP90 in PAH-PASMCs (data not shown) indicating that the beneficial effects of HDAC6 inhibition seen in our models cannot be ascribed to a weakening of HSP90 function. This evidence concerns the gene HDAC6 and pulmonary arterial hypertension.